{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:55:08Z","timestamp":1789188908731,"version":"build-2803163510"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,11,30]]},"DOI":"10.1097\/qad.0b013e3282f1560b","type":"journal-article","created":{"date-parts":[[2009,3,4]],"date-time":"2009-03-04T20:54:57Z","timestamp":1236200097000},"page":"2465-2472","source":"Crossref","is-referenced-by-count":15,"title":["Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV"],"prefix":"10.1097","volume":"21","author":[{"given":"Paolo","family":"Palma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Romiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Cancrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Pensieroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Montesano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilina B","family":"Santucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra M","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Castelli-Gattinara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210130","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1056\/NEJMoa011157","article-title":"Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1","volume":"345","author":"Gortmaker","year":"2001","journal-title":"N Engl J Med"},{"key":"R2-12-20210130","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jama.284.2.190","article-title":"Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry","volume":"284","author":"de Martino","year":"2000","journal-title":"JAMA"},{"key":"R3-12-20210130","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1651-2227.2003.tb00822.x","article-title":"Adherence to antiretroviral therapy and its determinants in children with human immunodeficiency virus infection: a multicentre, national study","volume":"92","author":"Giacomet","year":"2003","journal-title":"Acta Paediatr"},{"key":"R4-12-20210130","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00126334-200312010-00008","article-title":"Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort","volume":"34","author":"O'Brien","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R5-12-20210130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00006454-200301000-00015","article-title":"Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial","volume":"22","author":"Gibb","year":"2003","journal-title":"Pediatr Infect Dis"},{"key":"R6-12-20210130","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/00126334-200304150-00003","article-title":"Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children","volume":"32","author":"Vigano","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R7-12-20210130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1542\/peds.114.2.e235","article-title":"Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens","volume":"114","author":"Taylor","year":"2004","journal-title":"Pediatrics"},{"key":"R8-12-20210130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1468-1293.2005.00337.x","article-title":"Effects of highly active antiretroviral therapy on paediatric metabolite levels","volume":"7","author":"Rhoads","year":"2006","journal-title":"HIV Med"},{"key":"R9-12-20210130","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1097\/00002030-200409030-00004","article-title":"Metabolic complications of HIV therapy in children","volume":"18","author":"McComsey","year":"2004","journal-title":"AIDS"},{"key":"R10-12-20210130","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/01.qai.0000218344.88304.db","article-title":"Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999\u20132004: a longitudinal analysis","volume":"41","author":"Carter","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R11-12-20210130","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1468-1293.2002.00102.x","article-title":"Switch studies: a review","volume":"3","author":"Murphy","year":"2002","journal-title":"HIV Med"},{"key":"R12-12-20210130","first-page":"233","article-title":"Simplification of antiretroviral treatment: how to sustain success, reduce toxicity and ensure adherence avoiding PI use","volume":"4","author":"Barreiro","year":"2002","journal-title":"AIDS Rev"},{"key":"R13-12-20210130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/jac\/dkl191","article-title":"Benefits and concerns of simplification strategies in HIV-infected patients","volume":"58","author":"Negredo","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R14-12-20210130","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1097\/00002030-200411050-00019","article-title":"Long-term efficacy after switching from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine","volume":"18","author":"Opravil","year":"2004","journal-title":"AIDS"},{"key":"R15-12-20210130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/01.qai.0000164249.33851.3a","article-title":"Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART","volume":"39","author":"Bonjoch","year":"2005","journal-title":"J Acquir Immune Defic Synd"},{"key":"R16-12-20210130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.qai.0000169664.15536.20","article-title":"Induction with abacavir\/lamivudine\/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir\/lamivudine\/zidovudine alone in antiretroviral-naive HIV-1-infected patients","volume":"39","author":"Markowitz","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-12-20210130","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/jac\/dkh384","article-title":"The rise and fall of triple nucleoside reverse transcriptase inhibitor (NRTI) regimens","volume":"54","author":"Arribas","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 2","key":"R18-12-20210130","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1468-1293.2004.00227.x","article-title":"PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy","volume":"5","author":"Sharland","year":"2004","journal-title":"HIV Med"},{"key":"R19-12-20210130","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1203\/00006450-198003000-00004","article-title":"Plasma cholesterol and triglyceride distributions in 13 665 children and adolescents: the Prevalence Study of the Lipid Research Clinics Program","volume":"14","author":"Christensen","year":"1980","journal-title":"Pediatr Res"},{"key":"R20-12-20210130","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1097\/00002030-200111090-00002","article-title":"Kinetics of the T-cell receptor CD4 and CD8 V beta repertoire in HIV-1 vertically infected infants early treated with HAART","volume":"15","author":"Romiti","year":"2001","journal-title":"AIDS"},{"key":"R21-12-20210130","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/BF03402084","article-title":"Computer-based design of an HLA haplotype and HIV-clade independent cytotoxic T-lymphocyte assay for monitoring HIV-specific immunity","volume":"8","author":"Amicosante","year":"2002","journal-title":"Mol Med"},{"key":"R22-12-20210130","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1097\/01.aids.0000244211.33876.6f","article-title":"Switching from PI-based-HAART to PI-sparing regimen is associated with improved specific HIV-immune responses in HIV-infected children","volume":"20","author":"Pensieroso","year":"2006","journal-title":"AIDS"},{"key":"R23-12-20210130","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/jmv.20914","article-title":"Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens","volume":"79","author":"Sarmati","year":"2007","journal-title":"J Med Virol"},{"key":"R24-12-20210130","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jaci.2003.07.003","article-title":"Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study","volume":"112","author":"Shearer","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"R25-12-20210130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00148581-200406030-00002","article-title":"Triple nucleoside reverse transcriptase inhibitor therapy in children","volume":"6","author":"Handforth","year":"2004","journal-title":"Paediatr Drugs"},{"key":"R26-12-20210130","doi-asserted-by":"crossref","first-page":"9481","DOI":"10.1128\/JVI.76.18.9481-9492.2002","article-title":"Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure","volume":"76","author":"Ruff","year":"2002","journal-title":"J Virol"},{"key":"R27-12-20210130","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1086\/345860","article-title":"Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy","volume":"187","author":"Pellegrin","year":"2003","journal-title":"J Infect Dis"},{"key":"R28-12-20210130","first-page":"81","article-title":"Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review","volume":"29","author":"Re","year":"2006","journal-title":"New Microbiol"},{"key":"R29-12-20210130","doi-asserted-by":"crossref","first-page":"13120","DOI":"10.1073\/pnas.95.22.13120","article-title":"An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses","volume":"95","author":"Andre","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"R30-12-20210130","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/135965350501000203","article-title":"The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function","volume":"10","author":"Piccinini","year":"2005","journal-title":"Antivir Ther"},{"key":"R31-12-20210130","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/00002030-200203290-00004","article-title":"The human 26S proteasome is a target of antiretroviral agents","volume":"16","author":"Piccinini","year":"2002","journal-title":"AIDS"},{"key":"R32-12-20210130","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1097\/01.aids.0000186816.99993.8e","article-title":"Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients","volume":"19","author":"Legrand","year":"2005","journal-title":"AIDS"},{"key":"R33-12-20210130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/QAD.0b013e32801120bc","article-title":"Functional patterns of HIV-1-specific CD4T-cell responses in children are influenced by the extent of virus suppression and exposure","volume":"21","author":"Correa","year":"2007","journal-title":"AIDS"},{"key":"R34-12-20210130","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ni969","article-title":"Similarities and differences in CD4+ and CD8+ effector and memory T cell generation","volume":"4","author":"Seder","year":"2003","journal-title":"Nat Immunol"},{"key":"R35-12-20210130","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1542\/peds.107.1.e4","article-title":"A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team","volume":"107","author":"Saez-Llorens","year":"2001","journal-title":"Pediatrics"},{"key":"R36-12-20210130","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(02)07874-1","article-title":"Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial.","volume":"359","year":"2002","journal-title":"Lancet"},{"key":"R37-12-20210130","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00006454-200301000-00018","article-title":"Metabolic complications of antiretroviral therapy in children","volume":"22","author":"Leonard","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R38-12-20210130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1468-1293.2003.00139.x","article-title":"TRIZAL study: switching from successful HAART to Trizivir (abacavir\u2013lamivudine\u2013zidovudine combination tablet): 48 weeks efficacy, safety and adherence results","volume":"4","author":"Katlama","year":"2003","journal-title":"HIV Med"},{"key":"R39-12-20210130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2334-5-2","article-title":"Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment","volume":"5","author":"Keiser","year":"2005","journal-title":"BMC Infect Dis"},{"key":"R40-12-20210130","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1542\/peds.111.3.e275","article-title":"Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study","volume":"111","author":"Mc Comsey","year":"2003","journal-title":"Pediatrics"},{"key":"R41-12-20210130","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1177\/135965350501000807","article-title":"Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children","volume":"10","author":"Vigano","year":"2005","journal-title":"Antivir Ther"},{"key":"R42-12-20210130","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/archinte.161.22.2685","article-title":"Total cholesterol\/HDL cholesterol ratio vs LDL cholesterol\/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study","volume":"161","author":"Lemieux","year":"2001","journal-title":"Arch Intern Med"},{"key":"R43-12-20210130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.104.3.257","article-title":"Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction","volume":"104","author":"Stein","year":"2001","journal-title":"Circulation"},{"key":"R44-12-20210130","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/01.aids.0000131334.38172.01","article-title":"Antiretroviral therapy, fat redistribution and hyperlipidemia in HIV-infected children in Europe.","volume":"18","year":"2004","journal-title":"AIDS"},{"key":"R45-12-20210130","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/01.qai.0000139397.30612.96","article-title":"Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4\u201319 years) in PACTG 219C","volume":"38","author":"Farley","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 2","key":"R46-12-20210130","doi-asserted-by":"crossref","first-page":"M53","DOI":"10.1177\/135965350501002S06","article-title":"Nucleoside analogues toxicities related to mitochondrial dysfunction: focus on HIV-infected children","volume":"10","author":"Vigano","year":"2005","journal-title":"Antivir Ther"},{"key":"R47-12-20210130","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/135965350300800614","article-title":"Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level","volume":"8","author":"Nolan","year":"2003","journal-title":"Antivir Ther"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-200711300-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:44:21Z","timestamp":1786038261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200711300-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11,30]]},"references-count":47,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e3282f1560b","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11,30]]}}}